Imugene Limited (IMU.AX)

0,0820 -0,0030 (-3,53%) Al cierre: 04:10PM AEST

Imugene Limited

4-6 Bligh Street
Suite 12.01, Level 12
Sydney, NSW 2000
Australia
61 2 9423 0881
https://www.imugene.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD	Executive Chairman	316,1k	N/A	1956
Ms. Leslie Chong	CEO, MD & Executive Director	1,05M	N/A	N/A
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD	CFO & Company Secretary	424,28k	N/A	1966
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.	Head of Corporate Development	489,47k	N/A	N/A
Dr. Monil Shah M.B.A., Pharm.D.	Chief Business Officer	799,2k	N/A	N/A
Dr. Bradley Glover Ph.D.	Chief Operating Officer	N/A	N/A	1969
Ms. Ursula McCurry	Senior Vice President of Clinical Operations	N/A	N/A	N/A
Dr. John Byon	Senior Vice President of Clinical Development	N/A	N/A	N/A
Dr. Joseph Paul Woodard Jr., M.D.	Chief Medical Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en AUD.

Descripción

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Gobierno corporativo

El ISS Governance QualityScore de Imugene Limited, a día 1 de mayo de 2024, es 10. Las puntuaciones base son Auditoría: 9; Tablero: 8; Derechos de los accionistas: 1; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.